Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02255890
Recruitment Status : Recruiting
First Posted : October 3, 2014
Last Update Posted : February 4, 2019
Sponsor:
Information provided by (Responsible Party):
Clinical Research Office of the Endourological Society

Brief Summary:
The aim of this registry is to assess the recurrence of prostate cancer at 1 and 5 years, as well as the change in functional outcomes (e.g. incontinence or erectile function) from baseline. Secondary objectives are to establish which indications lead to treatment with IRE Nanoknife® setting and safety assessment measured by number of complications and adverse events.

Condition or disease
Prostate Cancer

Detailed Description:

This is an international prospective observational multi-center study in which data on consecutive patients for 5 years with prostate cancer who undergo IRE are collected. Data from each patient will be collected at participating centers over a 5-year period. Patients' data at baseline visit (pre-IRE), peri-operative data and follow up for 5 years will be recorded. Follow up data will be collected according to the following schedule:

1 - 2 weeks after surgery

  1. st year: every 3 months
  2. nd year: every three months
  3. rd year: every 6 months
  4. th and 5th year: once a year. Data from participating centers will be collected through electronic Case Report Forms (eCRFs), with use of an online Data Management System (DMS), which is located and maintained at the CROES Office. The data collection or patient participation in this study does not interfere with the choice of treatment, sample collection, procedures and the treatment itself, which should entirely follow standard hospital practices, including the follow up.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 2000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device; A Multi-Center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety.
Actual Study Start Date : November 2014
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer




Primary Outcome Measures :
  1. to assess the recurrence of prostate cancer at 1 and 5 years, as well as the change in functional outcomes (e.g. incontinence or erectile function) from baseline [ Time Frame: 10 years ]

Secondary Outcome Measures :
  1. to establish which indications lead to treatment with IRE Nanoknife® setting [ Time Frame: 5 years ]
  2. safety assessment measured by number of complications and adverse events [ Time Frame: 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The study population comprises those patients diagnosed with histologically confirmed prostate cancer and are scheduled for treatment with IRE Nanoknife®.
Criteria

Inclusion Criteria:

  • Is diagnosed with histologically confirmed prostate cancer
  • Is scheduled for IRE Nanoknife®
  • Has signed informed consent form

Exclusion Criteria:

  • No specific exclusion criteria are defined.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02255890


Contacts
Layout table for location contacts
Contact: Sonja van Rees Vellinga +31205666377 info@croesoffice.org

Locations
Layout table for location information
Netherlands
AMC University Hospital Recruiting
Amsterdam, Netherlands, 1105AZ
Contact: Jean de la Rosette         
Contact: Sonja van Rees Vellinga         
Sponsors and Collaborators
Clinical Research Office of the Endourological Society
Investigators
Layout table for investigator information
Study Chair: Jean de la Rosette Clinical Research Office of the Endourological Society

Additional Information:
Layout table for additonal information
Responsible Party: Clinical Research Office of the Endourological Society
ClinicalTrials.gov Identifier: NCT02255890     History of Changes
Other Study ID Numbers: Registry IRE Nanoknife®
First Posted: October 3, 2014    Key Record Dates
Last Update Posted: February 4, 2019
Last Verified: February 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases